Abstract: | Objective To investigate the application of three-dimensional speck tracking echocardiography in the evaluation of cardiotoxicity in trastuzumab treatment of breast cancer. Methods A total of 65 breast cancer patients treated with trastuzumab in the First Affiliated Hospital of Kunming Medical University from November 2020 to July 2022 were selected. Conventional echocardiography and three-dimensional speckle tracking technique (3D-STI) were performed 3, 6, 9, and 12 months after treatment. The differences in cardiac parameters at different time points were observed. The parameters included left ventricular ejection fraction (LVEF), left atrial volume index (LAVI), early diastolic mitral flow velocity/early diastolic mitral annular flow velocity (E/Em), early diastolic mitral annular flow velocity/late diastolic mitral annular flow velocity (Em/Am), early diastolic mitral annular flow velocity (Sm), and early diastolic mitral annular flow velocity (E/Em). Peak E), peak late diastolic mitral flow velocity (peak A), early diastolic mitral annular velocity (Em), late diastolic mitral annular velocity (Am), left ventricular torsion (LVtw), global longitudinal strain (GLS), global circumferential strain (GCS), global radial strain (GRS), global area strain (GAS). Results Compared with those before treatment, LAVI, E/Em and Am increased 3 months, 6 months, 9 months, and 12 months after treatment, while Em/Am and Em decreased. LAVI and E/Em were positively correlated. Compared with before and after treatment, LVEF, GLS, GRS, LVtw, GCS and GAS decreased 3, 6, 9 and 12 months after treatment (P < 0.05). Conclusions The application of three-dimensional echocardiographic speck tracking technology in the treatment of breast cancer patients with trastuzumab has an ideal effect, which can judge the cardiotoxicity more early and accurately, provide a reference for early treatment, and has value in improving prognosis and clinical outcome. |